Extracorporeal management of valproic acid overdose: A large regional experience

Journal of Nephrology

Volumn 17, Issue 1, 2004, Pages 43-49

  Singh, Sheldon M ^a   McCormick, Brendan B ^a   Mustata, Stefan ^a   Thompson, Margaret ^b   Ramesh Prasad, G V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Drug intoxication; Extracorporeal therapy; Hemadialysis; Hemoperfusion; Overdose; Poisoning; Valproic acid

Indexed keywords

ACTIVATED CARBON; BICARBONATE; HYPERTENSIVE AGENT; NALOXONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG OVERDOSE; FEMALE; HEMODIALYSIS; HEMOPERFUSION; HUMAN; INTENSIVE CARE; MALE; STATISTICAL ANALYSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE;

ADULT; EXTRACORPOREAL CIRCULATION; FEMALE; HALF-LIFE; HEMOPERFUSION; HUMANS; MALE; OVERDOSE; RENAL DIALYSIS; VALPROIC ACID;

EID: 1842502925     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brodie M, Dichter M. Antiepileptic drugs. N Engl J Med 1996; 334: 168-75.
2. Eisendrath SJ, Lichtmacher JE. Psychiatric disorders. In Tierney Jr. LM, McPhee SJ, Papdakis MA, Eds. Current Medical Diagnosis and Treatment. New York: Lange Medical Books/ McGraw Hill 2002; 1059-119.
3. Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, 2001. Annual report of the American Association of Poison Control Centres Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20: 391-452.
4. Spiller HA, Krenzelok EP, Klein-Schwartz W. Multicenter case series of valproic acid ingestion: Serum concentrations and toxicity. J Toxicol Clin Toxicol 2000; 38: 755-60.
5. Seger DL. Anticonvulsants. In Haddad LM, Shannon MW, Winchester JF, Eds. Clinical Management of Poisoning and Drug Overdose, (3rd ed). Philadelphia: WB Saunders 1998; 655-63.
6. Farrar HC, Herold DA, Reed MD. Acute valproic acid intoxication: Enhanced drug clearance with oral-activated charcoal. Crit Care Med 1993; 21: 299-301.
7. Graudins A, Aaron CK. Delayed peak serum valproic acid in massive divalproex overdose and treatment with charcoal hemoperfusion. J Toxicol Clin Toxicol 1996; 34: 335-41.
8. Roberge RJ, Francis EH 3rd. Use of naloxone in valproic acid overdose: Case report and review. J Emerg Med 2002; 22: 67-70.
9. Ishikura H, Matsuo N, Matsubara M, Ishihara T. Takeyama N. Tanaka T. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996; 20: 55-8.
10. Hicks LK, McFarlane PA. Valproic acid overdose and haemodialysis. Nephrol Dial Transplant 2001; 16: 1483-6.
11. Johnson LZ, Martinez I, Fernandez MC. Successful treatment of valproic acid overdose with hemodialysis. Am J Kidney Dis 1999; 33: 786-9.
12. Kane SL, Constantiner M, Staubus AE. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother 2000; 34: 1146-51.
13. Kroll P, Nand C. Hemodialysis in the treatment of valproic acid overdose. J Clin Psychiatry 2002; 63: 78-9.
14. Tank HE, Palmer BF. Simultaneous "iN series" hemodialysis and hemoperfusion in the management of valproic acid overdose. Am J Kidney Dis 1993; 2: 341-4.
15. Franssen EJ, van Essen GG, Portman AT. Valproic acid toxicokinetics: Serial hemodialysis and hemoperfusion. Ther Drug Monit 1999; 21: 289-92.
16. Kay TD, Playford HR, Johnson DW. Hemodialysis versus continuous veno-venous hemodiafiltration in the management of severe valproate overdose. Clin Nephrol 2003; 59: 56-8.
17. Dharnidharka VR, Fennell RS 3rd, Richard GA. Extracorporeal removal of toxic valproic acid levels in children. Pediatr Nephrol 2002; 17: 312-5.
18. Directory of Participating Dialysis Centres, Transplant Centres and Organ Procurement Organizations in Canada. Canadian Institute for Health Information, 2002; A27-55.
19. Van der Merwe AC, Albrecht CF, Brink MS, Coetzee AR. Sodium valproate poisoning: A case report. S Afr Med J 1985; 67: 735-6.
20. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1988; 15: 367-89.
21. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21: 736-43.
22. Brater DC. Treatment of renal disorders and the influence of renal function on drug deposition. In Melmon KL, Morrelli HF, Hoffman BB, Eds. Clinical Pharmacology. New York, NY: McGraw-Hill 1992; 290-308.
23. Bailey DN. Effect of co-administered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro. Ther Drug Monit 2001; 23: 71-4.